导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.06% | 929/4773 |
| 近一周 | -1.63% | 607/5462 |
| 近一月 | -2.16% | 1184/5421 |
| 近一季 | -2.90% | 1317/5209 |
| 近半年 | 1.82% | 1008/4920 |
| 近一年 | 11.67% | 898/4366 |
| 近两年 | 75.27% | 875/2954 |
| 近三年 | 51.05% | 521/2253 |
| 成立以来 | 60.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.45% 1547/4961 |
11.88% 2279/5312 |
- - |
- - |
| 2025 | 34.43% 1050/4813 |
1.52% 1606/3635 |
3.38% 1028/4076 |
25.58% 1388/4524 |
2.00% 1118/4813 |
| 2024 | 13.21% 1164/3463 |
3.71% 521/2808 |
-3.56% 1390/3014 |
17.22% 1237/3129 |
-3.44% 2345/3463 |
| 2023 | -12.30% 1466/2656 |
2.57% 1333/2280 |
-4.01% 1010/2385 |
-3.77% 984/2515 |
-7.45% 2153/2655 |
| 2022 | -20.32% 962/2207 |
-13.50% 768/1919 |
7.85% 422/2016 |
-13.00% 817/2113 |
-1.84% 1744/2208 |
| 2021 | -1.91% 825/1822 |
-2.26% 609/1255 |
5.06% 826/1330 |
-6.27% 912/1466 |
1.92% 751/1822 |
| 2020 | 33.96% 445/1250 |
-8.05% 587/1028 |
15.40% 505/1067 |
12.56% 379/1164 |
12.17% 496/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.00% 365/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 东方红中证竞争力指数C VS. 长安沪深300非周期A(740101) |